Humira (adalimumab) carries several serious, potentially life-threatening side effects that go well beyond the common injection-site reactions most patients experience. The drug’s FDA label includes a boxed warning, the agency’s strongest safety alert, for two categories: serious infections and certain cancers. These rare but severe risks are the tradeoff patients and doctors weigh against the benefits of controlling conditions like rheumatoid arthritis, Crohn’s disease, and psoriasis.
Serious Infections
Humira works by suppressing part of your immune system, specifically a protein called TNF-alpha that drives inflammation. The downside is that TNF-alpha also helps your body fight off bacteria, viruses, and fungi. With that defense weakened, infections that a healthy immune system would normally keep in check can take hold and spread.
The infections flagged in the boxed warning include tuberculosis (often reactivation of a latent infection you didn’t know you had), invasive fungal infections like histoplasmosis and aspergillosis, and bacterial infections from organisms like Legionella and Listeria. A meta-analysis of randomized trials found that patients on TNF-blocking drugs like Humira were roughly twice as likely to develop tuberculosis compared to control groups. TB in these patients often shows up in unusual forms, spreading beyond the lungs to other organs, which makes it harder to recognize and treat.
This is why you’ll be tested for latent tuberculosis before starting treatment. If the test is positive, you’ll need to begin TB treatment before your first dose of Humira. Beyond TB, any new fever, cough, flu-like symptoms, or wounds that won’t heal while on Humira warrant prompt medical attention, because even common infections can escalate quickly when your immune response is dialed down.
Lymphoma and Other Cancers
The second boxed warning covers malignancies. Lymphoma and other cancers, some fatal, have been reported in both adults and children taking TNF blockers. The specific concern that gets the most attention is hepatosplenic T-cell lymphoma (HSTCL), a rare and aggressive blood cancer. A review of reported cases identified 25 patients who developed HSTCL while on TNF-blocking therapy. The vast majority, 22 of the 25, had inflammatory bowel disease, and nearly all (96%) were also taking a second immune-suppressing medication such as azathioprine or methotrexate alongside their TNF blocker.
Only two of those 25 cases occurred in patients taking adalimumab alone, which suggests the combination of multiple immunosuppressants significantly raises the risk. HSTCL was originally thought to affect mainly young men, but the data now show it can also occur in women and adults over 65. While extremely rare, the cancer is aggressive enough that it remains a central part of the drug’s safety profile.
Demyelinating Nerve Disorders
TNF blockers have been linked to demyelinating diseases, conditions where the protective coating around nerve fibers breaks down. These include multiple sclerosis, optic neuritis (inflammation of the nerve connecting the eye to the brain), transverse myelitis (inflammation of the spinal cord), and peripheral nerve disorders like Guillain-Barré syndrome. Symptoms can range from vision changes and numbness to muscle weakness and difficulty walking.
If you have a personal or family history of MS or other demyelinating conditions, this is an important conversation to have before starting treatment. In some cases, symptoms have improved after stopping the drug, but not always. New onset of tingling, numbness, vision problems, or weakness in your arms or legs while on Humira should be evaluated quickly.
Heart Failure
Humira can worsen existing congestive heart failure or, less commonly, trigger new-onset heart failure. Across clinical trials in eight different conditions, heart failure events occurred at a rate of about 0.1 to 0.2 per 100 patient-years of treatment. That’s a low absolute number, but it’s meaningful if you already have a weakened heart. Patients with pre-existing heart failure are generally monitored more closely, and worsening symptoms like increased shortness of breath, sudden weight gain, or swelling in the legs may prompt discontinuation.
Hepatitis B Reactivation
If you carry the hepatitis B virus, even if your infection appeared to be resolved, Humira can reactivate it. Patients who test positive for the hepatitis B surface antigen are considered at high risk for reactivation. Even those who test negative for the surface antigen but positive for the core antibody (meaning they had a past infection) face a moderate risk. Reactivation can lead to serious liver damage, liver failure, and in some cases death. Screening for hepatitis B is standard before starting treatment, and carriers typically need antiviral therapy running alongside Humira.
Blood Cell Disorders
Humira has been associated with rare but serious drops in blood cell counts. Reported conditions include pancytopenia (a simultaneous drop in red blood cells, white blood cells, and platelets) and aplastic anemia, where the bone marrow stops producing enough new blood cells altogether. These are uncommon, but the warning signs are important to recognize: a fever that won’t go away, unusual bruising or bleeding, and looking noticeably pale. These symptoms reflect your body’s inability to fight infection, clot blood, or carry oxygen effectively.
Lupus-Like Reactions
Some patients on TNF blockers develop a condition that resembles lupus, with joint pain, skin rashes (including the butterfly-shaped facial rash characteristic of lupus), mouth sores, and chest pain from inflammation around the heart or lungs. In a Mayo Clinic case series of 14 patients who developed this syndrome over an eight-year period, all tested positive for antinuclear antibodies, 93% had arthritis, and 71% developed antibodies against their own DNA. Reassuringly, none developed kidney or neurological complications, and the syndrome typically resolves after stopping the medication.
Severe Allergic Reactions
Though not the most common concern, serious allergic reactions to Humira do occur. These can include hives, difficulty breathing, swelling of the face or throat, and in rare cases, full anaphylaxis. Milder injection-site reactions like redness, swelling, and itching are far more common and usually not dangerous, but a reaction that involves breathing difficulty or widespread swelling is a medical emergency.
How These Risks Are Managed
Before you start Humira, expect a round of screening that includes testing for tuberculosis and hepatitis B at minimum. Your doctor will also review your history for heart failure, neurological conditions, and any prior cancers. Once on the drug, regular blood work helps catch early signs of liver problems or dropping blood cell counts.
Most of these severe side effects are rare. The common side effects patients actually deal with day to day, like upper respiratory infections, headaches, injection-site reactions, and rashes, are far less dramatic. But the serious risks are real enough that the FDA requires its strongest warning label, and understanding them helps you recognize problems early, when they’re most treatable.